Hospital purchasing group Civica Rx says it is interested in talking to generics manufacturers which are considering retiring or withdrawing their abbreviated new drug applications for essential medicines that are at risk of being in short supply.
Civica Interested In Retired Or Withdrawn ANDAs
Seeks Talks With Manufacturers Over 250 ANDAs For Essential Medicines
As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.
More from Strategy
More from Business
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.